Vicore Pharma Holding AB ... (VCRE)
Vicore Pharma Holding AB (publ) (VCRE) Stock Price, Analysis & Data
| Bid | 11.34 |
| Market Cap | 344.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Beta | 0.12 |
| EPS (ttm) | -2 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.07 |
| P/B (ttm) | n/a |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 11.31 |
| Volume | 3,159 |
| Avg. Volume (20D) | 30,453 |
| Open | 11.86 |
| Previous Close | 12.23 |
| Day's Range | 11.79 - 11.86 |
| 52-Week Range | 10.50 - 17.80 |
| Analyst | n/a |
| Price Target | 35.08 (196.79%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VCRE
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also develop...
Financial Performance
In 2025, Vicore Pharma AB (publ)'s revenue was 3.82M, a decrease of -96.51% compared to the previous year's 109.35M. Earnings were -477.47M, an increase of 183.14%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for VCRE stock is "null". The 12-month stock price forecast is 35.08, which is upside of 196.79% from the latest price.
Stock Forecasts